Cochrane · systematic review · CD010155
Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease
van Zuuren, EJ, Fedorowicz, Z · Cochrane Database of Systematic Reviews · 2015 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
18
current version
GRADE rated
6
No studies
12
Included studies
NR
No studies 12 · 66.7%Ungraded 0 · 0%Very low 5 · 27.8%Low 1 · 5.6%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyTinzaparin compared to placebo for people with sickle cell disease
Population: people with sickle cell disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Pain intensityNumeric pain scale Tinzaparin vs placebo | no estimate extracted | 1 study · 253 participants | Very low Downgraded: risk of bias, imprecision |
Pain durationScale from: 1 to 7. Tinzaparin vs placebo | no estimate extracted | 1 study · 253 participants | Very low Downgraded: risk of bias, imprecision |
The requirement for opiate treatment Tinzaparin vs placebo | no estimate extracted | 1 study · 253 participants | Very low Downgraded: risk of bias, imprecision |
Number of serious complications of SCD ‐ not measured Tinzaparin vs placebo | no estimate extracted | NR | No studies |
Number of other sickle‐related events ‐ not measured Tinzaparin vs placebo | no estimate extracted | NR | No studies |
Quality of life (e.g. absence from school, lost time at work, mobility) as assessed by any validated questionnaire either generic or SCD specific) ‐ not measured Tinzaparin vs placebo | no estimate extracted | NR | No studies |
Hospitalisation (number and duration)Scale from: 0 to 12. Tinzaparin vs placebo | no estimate extracted | 1 study · 253 participants | Very low Downgraded: risk of bias, imprecision |
Participant satisfaction with the medication assessed by any appropriate and validated questionnaire (either generic or SCD specific) ‐ not measured Tinzaparin vs placebo | no estimate extracted | NR | No studies |
Adverse events associated with the use of anticoagulants (e.g. bleeding) Tinzaparin vs placebo | RR 4.96 [0.24, 102.31] | 1 study · 253 participants | Low Downgraded: risk of bias, imprecision |
Dalteparin compared to placebo for people with sickle cell disease
Population: patients with people with sickle cell disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Pain intensityVAS 0‐10. Scale from: 0 to 10. Dalteparin vs placebo | no estimate extracted | 1 study · 35 participants | Very low Downgraded: risk of bias, imprecision |
Pain duration ‐ not measured Dalteparin vs placebo | no estimate extracted | NR | No studies |
The requirement for opiate treatment ‐ not measured Dalteparin vs placebo | no estimate extracted | NR | No studies |
Number of serious complications of SCD ‐ not measured Dalteparin vs placebo | no estimate extracted | NR | No studies |
Number of other sickle‐related events ‐ not measured Dalteparin vs placebo | no estimate extracted | NR | No studies |
Quality of life (e.g. absence from school, lost time at work, mobility) as assessed by any validated questionnaire either generic or SCD specific) ‐ not measured Dalteparin vs placebo | no estimate extracted | NR | No studies |
Hospitalisation (number and duration) ‐ not measured Dalteparin vs placebo | no estimate extracted | NR | No studies |
Participant satisfaction with the medication assessed by any appropriate and validated questionnaire (either generic or SCD specific) ‐ not measured Dalteparin vs placebo | no estimate extracted | NR | No studies |
Adverse events associated with the use of anticoagulants (e.g. bleeding) ‐ not measured Dalteparin vs placebo | no estimate extracted | NR | No studies |
Tinzaparin compared to placebo for people with sickle cell disease
Population: people with sickle cell disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
pain intensity Numerical pain scale Tinzaparin vs placebo | no estimate extracted | 1 study · 253 participants | Low Downgraded: risk of bias |
pain duration Scale from 1 to 7 Tinzaparin vs placebo | no estimate extracted | 1 study · 253 participants | Moderate Downgraded: risk of bias |
the requirement for opiate treatment Tinzaparin vs placebo | no estimate extracted | 1 study · 253 participants | Low Downgraded: risk of bias |
number of serious complications of SCD4 － not reported Tinzaparin vs placebo | no estimate extracted | NR | No studies |
number of other sickle‐related events4 － not reported Tinzaparin vs placebo | no estimate extracted | NR | No studies |
quality of life (e.g. absence from school, lost time at work, mobility) as assessed by any validated questionnaire, either generic or SCD specific4 － not reported Tinzaparin vs placebo | no estimate extracted | NR | No studies |
hospitalisation (number and duration) Scale from 0 to 12. Tinzaparin vs placebo | no estimate extracted | 1 study · 253 participants | Low Downgraded: risk of bias |
participant satisfaction with the medication assessed by any appropriate and validated questionnaire (either generic or SCD specific) Tinzaparin vs placebo | no estimate extracted | NR | No studies |
adverse events associated with the use of anticoagulants (e.g. bleeding) Tinzaparin vs placebo | RR 4.96 [0.24, 102.31] | 1 study · 253 participants | High |